Completed PHASE3 INTERVENTIONAL 2-arm NCT00182143

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

Sponsor: Australian and New Zealand Intensive Care Society Clinical Trials Group

Conditions Critical Illness Deep Venous Thrombosis

Interventions LMWH (Fragmin, dalteparin) Unfractionated Heparin

Updated 6 times since 2017 Last updated: Jan 7, 2011 Started: May 31, 2006 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Critical Illness and Deep Venous Thrombosis, this trial is completed. The trial is conducted by Australian and New Zealand Intensive Care Society Clinical Trials Group and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australian and New Zealand Intensive Care Society Clinical Trials Group
Canadian Critical Care Trials Group
Canadian Institutes of Health Research (CIHR)
McMaster University

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Bedford Park, Australia , Bendigo, Australia , Blacktown, Australia , Box Hill, Australia , Calgary, Canada , Camperdown, Australia , Clayton, Australia , Dandenong, Australia , Edmonton, Canada and 34 more locations